Nolato (NOLA) investor relations material

Executive summary

• Q1 2026 sales reached SEK 2,357 million, with 3% organic growth year-over-year adjusted for currency, led by Medical Solutions up 5% and Engineered Solutions up 1%.

• EBITA was SEK 260 million, with a stable margin of 11.0% despite 7% currency headwinds.

• Profit after tax was SEK 181 million, and earnings per share were SEK 0.67, both slightly lower than the prior year.

• Cash flow from operating activities improved to SEK 225 million, reflecting operational efficiency.

• Strong financial position with net financial liabilities/EBITDA at 0.5x and equity/assets ratio of 60%, supporting acquisition and expansion agendas.

Financial highlights

• Net sales were SEK 2,357 million, down from SEK 2,453 million year-over-year, but up 3% currency-adjusted.

• EBITA was SEK 260 million (down from SEK 271 million), with an 11.0% margin.

• Profit after tax was SEK 181 million, and earnings per share were SEK 0.67.

• Cash flow from operations increased to SEK 225 million; cash flow after investments was SEK 32 million (up from -SEK 136 million).

• Return on capital employed was 14% for the last 12 months.

Outlook and guidance

• Anticipates 5%-10% increase in material input costs in the near term, with most impact in Q2 and spillover into Q3.

• Margin normalization expected by Q3 as price increases are passed to customers with a 3-4 month lag.

• CapEx guidance for 2026 remains SEK 650–700 million.

• Expansion projects in Hungary, Malaysia, and Poland are ongoing, with commercial volumes from Hungary expected late Q2.

• Strong financial position enables intensified M&A agenda and focus on new materials and technologies.